We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer’s Lorbrena Shows Strong Benefit in Lung Cancer Study
Pfizer’s Lorbrena Shows Strong Benefit in Lung Cancer Study
Pfizer has released promising results from a global phase 3 trial of its non-small cell lung cancer (NSCLC) investigational treatment, Lorbrena (lorlatinib).